-+ 0.00%
-+ 0.00%
-+ 0.00%

Cerenome’s REYOBIQ combination extends survival in ovarian cancer mouse models

PUBT·10/21/2026 11:30:43
Listen to the news
Cerenome’s REYOBIQ combination extends survival in ovarian cancer mouse models
  • Cerenome announced preclinical results suggesting investigational radiotherapeutic REYOBIQ damages tumor DNA and reduces immune suppression in two ovarian cancer mouse models.
  • Combining REYOBIQ with anti-PD-1 checkpoint blockade extended median survival to 65 days, outperforming controls or either treatment alone.
  • The combination reduced tumor burden without evidence of substantial added toxicity, supporting further development of checkpoint inhibitor combinations.
  • DNA-damage responses began within 24 hours; immune activation increased by Day 28.
  • REYOBIQ improved survival dose-dependently across 0.075 to 1.257 mCi in the ID8agg model (p = 0.0003).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210730PRIMZONEFULLFEED9850009) on October 21, 2026, and is solely responsible for the information contained therein.